Spider peptide toxins as leads for drug development

Expert Opinion on Drug Discovery

Volumn 2, Issue 6, 2007, Pages 823-835

  Escoubas, Pierre ^a   Bosmans, Frank ^b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Drug discovery; Ion channels; Mass spectrometry; Pain; Peptide toxins; Spider venom

Indexed keywords

ACETYLSALICYLIC ACID; ACID SENSING ION CHANNEL; AMILORIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARTHROPOD VENOM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM CHANNEL R TYPE; CYCLOOXYGENASE 2 INHIBITOR; CYSTINE; DISULFIDE; FLURBIPROFEN; IBUPROFEN; ION CHANNEL; LATROTOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA AGATOXIN; OPIATE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KV1.4; SODIUM CHANNEL BLOCKING AGENT; SPIDER VENOM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

AMINO ACID SEQUENCE; ANALGESIA; ANALYTIC METHOD; CARDIOVASCULAR DISEASE; CHANNEL GATING; COMBINATORIAL LIBRARY; DISULFIDE BOND; DRUG RESEARCH; DRUG TARGETING; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NATURAL SELECTION; NEUROMUSCULAR DISEASE; NOCICEPTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAIN; PREDATOR PREY INTERACTION; PRIORITY JOURNAL; PROTEIN MOTIF; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT;

EID: 34548081279     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.6.823     Document Type: Review

References (117)

1. LEWIS RJ, GARCIA ML: Therapeutic potential of venom peptides. Nat. Rev. Drug Discov. (2003) 2(10):790-802.
2. OLIVERA BM, RIVIER J, CLARK C et al.: Diversity of Conus neuropeptides. Science (1990) 249(4966):257-263.
3. DALY JW, GARRAFFO HM, SPANDE TF, DECKER MW, SULLIVAN JP, WILLIAMS M: Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics. Nat. Prod. Rep. (2000) 17(2):131-135.
4. KLOTZ U: Ziconotide - a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain - a short review. Int. J. Clin. Pharmacol. Ther. (2006) 44(10):478-483.
5. MCGIVERN JG: Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov. Today (2006) 11(5-6):245-253.
6. KOH DC, ARMUGAM A, JEYASEELAN K: Snake venom components and their applications in biomedicine. Cell Mol. Life Sci. (2006) 63(24):3030-3041.
7. BUCZEK O, BULAJ G, OLIVERA BM: Conotoxins and the posttranslational modification of secreted gene products. Cell Mol. Life Sci. (2005) 62(24):3067-3079.
8. OLIVERA BM: Conus peptides: biodiversity-based discovery and exogenomics. J. Biol. Chem. (2006) 281(42):31173-31177.
9. MENEZ A: Functional architectures of animal toxins: a clue to drug design? Toxicon (1998) 36(11):1557-1572.
10. TERLAU H, OLIVERA BM: Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol. Rev. (2004) 84(1):41-68.
11. ESCOUBAS P, DIOCHOT S, CORZO G: Structure and pharmacology of spider venom neurotoxins. Biochimie (2000) 82(9-10):893-907.
12. RASH LD, HODGSON WC: Pharmacology and biochemistry of spider venoms. Toxicon (2002) 40(3):225-254.
13. CABBINESS SG, GEHRKE CW, KUO KC et al.: Polyamines in some tarantula venoms. Toxicon (1980) 18(5-6):681-683.
14. TZOUROS M, CHESNOV S, BIENZ S, HESSE M, BIGLER L: New linear polyamine derivatives in spider venoms. Toxicon (2005) 46(3):350-354.
15. STROMGAARD K, JENSEN LS, VOGENSEN SB: Polyamine toxins: development of selective ligands for ionotropic receptors. Toxicon (2005) 45(3):249-254.
16. WILLIAMS K: Interactions of polyamines with ion channels. Biochem. J. (1997) 325(Pt 2):289-297.
17. GRISHIN E: Polypeptide neurotoxins from spider venoms. Eur. J. Biochem. (1999) 264(2):276-280.
18. PIMENTA AM, DE LIMA ME: Small peptides, big world: biotechnological potential in neglected bioactive peptides from arthropod venoms. J. Pept. Sci. (2005) 11(11):670-676.
19. ESCOUBAS P, CÉLÉRIER M-L, ROMI-LEBRUN R, NAKAJIMA T: Two novel peptide toxins from the venom of the tarantula. Lasiodora parahybana. Toxicon (1997) 35(6):805.
20. CASSOLA AC, JAFFE H, FALES HM, CASTRO AFECHE S, MAGNOLI F, CIPOLLA-NETO J: Omega-phonetoxin-IIA: a calcium channel blocker from the spider Phoneutria nigriventer. Pflugers Arch. (1998) 436(4):545-552.
21. GOMEZ MV, KALAPOTHAKIS E, GUATIMOSIM C, PRADO MA: Phoneutria nigriventer venom: a cocktail of toxins that affection channels. Cell Mol. Neurobiol. (2002) 22(5-6):579-588.
22. WEN S, WILSON DT, KURUPPU S et al.: Discovery of an MIT-like atracotoxin family: spider venom peptides that share sequence homology but not pharmacological properties with AVIT family proteins. Peptides (2005) 26(12):2412-2426.
23. SUTTON KG, SIOK C, STEA A et al.: Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW 13.3. Mol. Pharmacol. (1998) 54(2):407-418.
24. LIANG S: An overview of peptide toxins from the venom of the Chinese bird spider Selenocosmia huwena Wang [=Ornithoctonus huwena (Wang)]. Toxicon (2004) 43(5):575-585.
25. JOHNSON J H, BLOOMQUIST JR, KRAPCHO KJ et al.: Novel insecticidal peptides from Tegenaria agrestis spider venom may have a direct effect on the insect central nervous system. Arch. Insect Biochem. Physiol. (1998) 38(1):19-31.
26. VENEMA VJ, SWIDEREK KM, LEE TD, HATHAWAY GM, ADAMS ME: Antagonism of synaptosomal calcium channels by subtypes of omega-agatoxins. J. Biol. Chem. (1992) 267(4):2610-2615.
27. SKINNER WS, DENNIS PA, LI JP, QUISTAD GB: Identification of insecticidal peptides from venom of the trap-door spider, Aptostichus schlingeri (Ctenizidae). Toxicon (1992) 30(9):1043-1050.
28. ESCOUBAS P: Molecular diversification in spider venoms: a web of combinatorial peptide libraries. Mol. Divers. (2006) 10(4):545-554.
29. NORTON RS, PALLAGHY PK: The cystine knot structure of ion channel toxins and related polypeptides. Toxicon (1998) 36(11):1573-1583.
30. CRAIK DJ, DALY NL, WAINE C: The cystine knot motif in toxins and implications for drug design. Toxicon (2001) 39(1):43-60.
31. WANG X, CONNOR M, SMITH R et al.: Discovery and characterization of a family of insecticidal neurotoxins with a rare vicinal disuffide bridge. Nat. Struct. Biol. (2000) 7(6):505-513.
32. SHU Q, LU SY, GU XC, LIANG SP: Sequence-specific assignment of (1)H-NMR resonance and determination of the secondary structure of HWTX-II. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (2001) 33(1):65-70.
33. SHU Q, LU SY, GU XC, LIANG SP: The structure of spider toxin huwentoxin-II with unique disulfide linkage: evidence for structural evolution. Protein Sci. (2002) 11(2):245-252.
34. ESCOUBAS P: Mass spectrometry in toxicology: a 21st-century technology for the study of biopolymers from venoms. Toxicon (2006) 47(6):609-613.
35. ESCOUBAS P, CELERIER ML, NAKAJIMA T: High-performance liquid chromatography matrix-assisted laser desorption/ionization time-of-flight mass spectrometry peptide fingerprinting of tarantula venoms in the genus Brachypelma: chemotaxonomic and biochemical applications. Rapid Commun. Mass Spectrom. (1997) 11(17):1891-1899.
36. ESCOUBAS P, CHAMOT-ROOKE J, STOCKLIN R et al.: A comparison of matrix-assisted laser desorption/ionization time-of-flight and liquid chromatography electrospray ionization mass spectrometry methods for the analysis of crude tarantula venoms in the Pterinochilus group. Rapid Commun. Mass Spectrom. (1999) 13(18):1861-1868.
37. ESCOUBAS P, CORZO G, WHITELEY BJ, CELERIER ML, NAKAJIMA T: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and high-performance liquid chromatography study of quantitative and qualitative variation in tarantula spider venoms. Rapid Commun. Mass Spectrom. (2002) 16(5):403-413.
38. NASCIMENTO DG, RATES B, SANTOS DM et al.: Moving pieces in a taxonomic puzzle: venom 2D-LC/MS and data clustering analyses to infer phylogenetic relationships in some scorpions from the Buthidae family (Scorpiones). Toxicon (2006) 47(6):628-639.
39. PIMENTA AM, RATES B, BLOCH C JR et al.: Electrospray ionization quadrupole time-of-flight and matrix-assisted laser desorption/ ionization tandem time-of-flight mass spectrometric analyses to solve micro-heterogeneity in post-translationally modified pepcides from Phoneutria nigriventer (Aranea, Crenidae) venom. Rapid Commun. Mass Spectrom. (2005) 19(1):31-37.
40. PIMENTA AM, STOCKLIN R, FAVREAU P, BOUGIS PE, MARTIN-FAUCLAIRE MF: Moving pieces in a proteomic puzzle: mass fingerprinting of toxic fractions from the venom of Tityus serrulatus (Scorpiones, Buthidae). Rapid Commun. Mass Spectrom. (2001) 15(17):1562-1572.
41. VIANNA BRAGA MC, KONNO K, PORTARO FC et al.: Mass spectrometric and high performance liquid chromatography profiling of the venom of the Brazilian vermivorous mollusk Conus regius: feeding behavior and identification of one novel conotoxin. Toxicon (2005) 45(1):113-122.
42. GUETTE C, LEGROS C, TOURNOIS G, GOYFFON M, CELERIER ML: Peptide profiling by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry of the Lasiodora parahybana tarantula venom gland. Toxicon (2006) 47(6):640-649.
43. WILSON D, ALEWOOD PF: Taxonomy of Australian funnel-web spiders using rp-HPLC/ESI-MS profiling techniques. Toxicon (2006) 47(6):614-627.
44. ESCOUBAS P, SOLLOD B, KING GF: Venom landscapes: mining the complexity of spider venoms via a combined cDNA and mass spectrometric approach. Toxicon (2006) 47(6):650-663.
45. SOLLOD BL, WILSON D, ZHAXYBAYEVA O, GOGARTEN JP, DRINKWATER R, KING GF: Were arachnids the first to use combinatorial peptide libraries? Peptides (2005) 26(1):131-139.
46. ESCOUBAS P, RASH L: Tarantulas: eight-legged pharmacists and combinatorial chemists. Toxicon (2004) 43(5):555-574.
47. CORZO G, ESCOUBAS P: Pharmacologically active spider peptide toxins. Cell. Mol. Life Sci. (2003) 60(11):2409-2426.
48. ESTRADA G, VILLEGAS E, CORZO G: Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs. Nat. Prod. Rep. (2007) 24(1):145-161.
49. SIEMENS J, ZHOU S, PISKOROWSKI R et al.: Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature (2006) 444(7116):208-212.
50. + channels. Ann. NY Acad. Sci. (1999) 868:233-285.
51. + channel through multiple binding sites. Neuron (1997) 18(4):665-673.
52. SWARTZ KJ, MACKINNON R: An inhibitor of the Kv2.1 potassium channel isolated from the venom of a Chilean tarantula. Neuron (1995) 15(4):941-949.
53. SANGUINETTI MC, JOHNSON JH, HAMMERLAND LG et al.: Heteropodatoxins: peptides isolated from spider venom that block Kv4.2 potassium channels. Mol. Pharmacol. (1997) 51(3):491-498.
54. DIOCHOT S, DRICI MD, MOINIER D, FINK M, LAZDUNSKI M: Effects of phrixotoxins on the Kv4 family of potassium channels and implications for the role of Ito1 in cardiac electrogenesis. Br. J. Pharmacol. (1999) 126(1):251-263.
55. ESCOUBAS P, DIOCHOT S, CELERIER ML, NAKAJIMA T, LAZDUNSKI M: Novel tarantula toxins for subtypes of voltage-dependent potassium channels in the Kv2 and Kv4 subfamilies. Mol. Pharmacol. (2002) 62(1):48-57.
56. MARVIN L, DE E, COSETTE P, GAGNON J, MOLLE G, LANGE C: Isolation, amino acid sequence and functional assays of SGTx1. The first toxin purified from the venom of the spider Scodra griseipes. Eur. J. Biochem. (1999) 265(2):572-579.
57. + channels. Toxicon (2003) 41(3):305-313.
58. ADAMS ME, BINDOKAS VP, HASEGAWA L, VENEMA VJ: Omega-agatoxins: novel calcium channel antagonists of two subtypes from funnel web spider ( Agelenopsis aperta) venom. J. Biol. Chem. (1990) 265(2):861-867.
59. LEUNG HT, BRANTON WD, PHILLIPS HS, JAN L, BYERLY L: Spider toxins selectively block calcium currents in Drosophila. Neuron (1989) 3(6):767-772.
60. 2+ channel subtypes in cultured rat hippocampal neurons. Mol. Pharmacol. (1995) 48(1):131-139.
61. NEWCOMB R, PALMA A, FOX J et al.: SNX-325, a novel calcium antagonist from the spider Segestria florentina. Biochemistry (1995) 34(26):8341-8347.
62. PENG K, CHEN XD, LIANG SP: The effect of Huwentoxin-I on Ca(2+) channels in differentiated NG108-15 cells, a patch-clamp study. Toxicon (2001) 39(4):491-498.
63. NEWCOMB R, SZOKE B, PALMA A et al.: Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry (1998) 37(44):15353-15362.
64. DOS SANTOS RG, VAN RENTERGHEM C, MARTIN-MOUTOT N et al.: Phoneutria nigriventer omega-phonetoxin ILA blocks the Cav2 family of calcium channels and interacts with omega-conotoxin-binding sites. J. Biol. Chem. (2002) 277(16):13856-13862.
65. GOLDIN AL, BARCHI RL, CALDWELL JH et al.: Nomenclature of voltage-gated sodium channels. Neuron (2000) 28(2):365-368.
66. AMIR R, ARGOFF CE, BENNETT GJ et al.: The role of sodium channels in chronic inflammatory and neuropathic pain. J. Pain (2006) 7(5 Suppl. 3):S1-S29.
67. WOOD JN: Ion channels in analgesia research. Handbook Exp. Pharmacol. (2007) 177:329-358.
68. NICHOLSON GM, LITTLE MJ, BIRINYI-STRACHAN LC: Structure and function of delta-atracotoxins: lethal neurotoxins targeting the voltage-gated sodium channel. Toxicon (2004) 43(5):587-599.
69. TEDFORD HW, SOLLOD BL, MAGGIO F, KING GF: Australian funnel-web spiders: master insecticide chemists. Toxicon (2004) 43(5):601-618.
70. ADAMS ME, HEROLD EE, VENEMA VJ: Two classes of channel-specific toxins from funnel web spider venom. J. Comp. Physiol. [A] (1989) 164(3):333-342.
71. STAPLETON A, BLANKENSHIP DT, ACKERMANN BL et al.: Curtatoxins. Neurotoxic insecticidal polypeptides isolated from the funnel-web spider Hololena curta. J. Biol. Chem. (1990) 265(4):2054-2059.
72. CORZO G, ESCOUBAS P, STANKIEWICZ M, PELHATE M, KRISTENSEN CP, NAKAJIMA T: Isolation, synthesis and pharmacological characterization of delta-palutoxins IT, novel insecticidal toxins from the spider Paracoelotes luctuosus (Amaurobiidae). Eur. J. Biochem. (2000) 267(18):5783-5795.
73. MIDDLETON RE, WARREN VA, KRAUS RL et al.: Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry (2002) 41(50):14734-14747.
74. BOSMANS F, RASH L, ZHU S et al.: Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes. Mol. Pharmacol. (2006) 69(2):419-429.
75. WALDMANN R: Proton-gated cation channels - neuronal acid sensors in the central and peripheral nervous system. Adv. Exp. Med. Biol. (2001) 502:293-304.
76. + channels. J. Biol. Chem. (2000) 275(33):25116-25121.
77. CHEN X, KALBACHER H, GRUNDER S: Interaction of acid-sensing ion channel (ASIC) 1 with the tarantula toxin psalmotoxin 1 is state dependent. J. Gen. Physiol. (2006) 127(3):267-276.
78. SALINAS M, RASH LD, BARON A, LAMBEAU G, ESCOUBAS P, LAZDUNSKI M: The receptor site of the spider toxin PcTx1 on the proton-gated cation channel ASIC1a. J. Physiol. (2006) 570(Pt 2):339-354.
79. + affinity. J. Gen. Physiol. (2005) 126(1):71-79.
80. GITTERMAN DP, WILSON J, RANDALL AD: Functional properties and pharmacological inhibition of ASIC channels in the human SJ-RH30 skeletal muscle cell line. J. Physiol. (2005) 562(Pt 3):759-769.
81. + channels by psalmotoxin 1. Am. J. Physiol. Cell Physiol. (2004) 287(5):C1282-C1291.
82. GOTTLIEB PA, SUCHYNA TM, OSTROW LW, SACHS F: Mechanosensitive ion channels as drug targets. Curr. Drug Targets CNS Neurol. Disord. (2004) 3(4):287-295.
83. BODE F, SACHS F, FRANZ MR: Tarantula peptide inhibits atrial fibrillation. Nature (2001) 409(6816):35-36.
84. RODEN DM, BALSER JR, GEORGE AL JR, ANDERSON ME: Cardiac ion channels. Ann. Rev. Physiol. (2002) 64:431-475.
85. KOMUKAI K, BRETTE F, YAMANUSHI TT, ORCHARD CH: K(+) current distribution in rat sub-epicardial ventricular myocytes. Pflugers Arch. (2002) 444(4):532-538.
86. ISBRANDT D, LEICHERT, WALDSCHUTZ R et al.: Gene structures and expression profiles of three human KCND (Kv4) potassium channels mediating A-type currents I(TO) and I(SA). Genomics (2000) 64(2):144-154.
87. SUCHYNA TM, TAPE SE, KOEPPE RE 2ND, ANDERSEN OS, SACHS F, GOTTLIEB PA: Bilayer-dependent inhibition of mechanosensitive channels by neuroactive peptide enantiomers. Nature(2004) 430(6996):235-240.
88. OSWALD RE, SUCHYNA TM, MCFEETERS R, GOTTLIEB P, SACHS F: Solution structure of peptide toxins that block mechanosensitive ion channels. J. Biol. Chem. (2002) 277(37):34443-34450.
89. XIAO Y, TANG J, YANG Y et al.: Jingzhaotoxin-III, a novel spider toxin inhibiting activation of voltage-gated sodium channel in rat cardiac myocyces. J. Biol. Chem. (2004) 279(25):26220-26226.
90. XIAO Y, TANG J, HU W et al.: Jingzhaotoxin-1, a novel spider neurotoxin preferentially inhibiting cardiac sodium channel inactivation. J. Biol. Chem. (2005) 280(13):12069-12076.
91. JACOBS T: No pain, no gain? Nat. Biotechnol. (2005) 23(8):934.
92. WALDMANN R, CHAMPIGNY G, LINGUEGLIA E, DE WEILLE JR, HEURTEAUX C, LAZDUNSKI M: H(+)-gated cation channels. Ann. NY Acad. Sci. (1999) 868:67-76.
93. JONES NG, SLATER R, CADIOU H, MCNAUGHTON P, MCMAHON SB: Acid-induced pain and its modulation in humans. J. Neurosci. (2004) 24(48):10974-10979.
94. VOILLEY N: Acid-sensing ion channels (ASICs): new targets for the analgesic effects of non-steroid anti-inflammatory drugs (NSAIDs). Curr. Drug Targets Inflamm. Allergy (2004) 3(1):71-79.
95. CHEN CC, ZIMMER A, SUN WH, HALL J, BROWNSTEIN MJ, ZIMMER A: A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc. Natl. Acad. Sci. USA (2002) 99(13):8992-8997.
96. MOGIL JS, BREESE NM, WITTY MF et al.: Transgenic expression of a dominant-negative ASIC3 subunit leads to increased sensitivity to mechanical and inflammatory stimuli. J. Neurosci. (2005) 25(43):9893-9901.
97. SLUKA KA, RADHAKRISHNAN R, BENSON CJ et al.: ASIC3 in muscle mediates mechanical, but not heat, hyperalgesia associated with muscle inflammation. Pain (2006).
98. SLUKA KA, PRICE MP, BREESE NM, STUCKY CL, WEMMIE JA, WELSH MJ: Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1. Pain (2003) 106(3):229-239.
99. DIOCHOT S, BARON A, RASH LD et al.: A new sea anemone peptide, APETx2, inhibits ASIC3, a major acid-sensitive channel in sensory neurons. EMBO J. (2004) 23(7):1516-1525.
100. WOOD JN, BOORMAN JP, OKUSE K, BAKER MD: Voltage-gared sodium channels and pain pathways. J. Neurobiol. (2004) 61(1):55-71.
101. HAINS BC, SAAB CY, WAXMAN SG: Changes in electrophysiological properties and sodium channel Nav1.3 expression in thalamic neurons after spinal cord injury. Brain (2005) 128(Pt 10):2359-2371.
102. LINDIA JA, KOHLER MG, MARTIN WJ, ABBADIE C: Relationship between sodium channel NaV1.3 expression and neuropachic pain behavior in rats. Pain (2005) 117(1-2):145-153.
103. HAINS BC, KLEIN JP, SAAB CY, CRANER MJ, BLACK JA, WAXMAN SG: Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J. Neurosci. (2003) 23(26):8881-8892.
104. AKOPIAN AN, SOUSLOVA V, ENGLAND S et al.: The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. (1999) 2(6):541-548.
105. CERVERO F, LAIRD JM: Role of ion channels in mechanisms controlling gastrointestinal pain pathways. Curr. Opin. Pharmacol. (2003) 3(6):608-612.
106. DIB-HAJJ S, BLACK JA, CUMMINS TR, WAXMAN SG: NaN/Nav1.9: a sodium channel with unique properties. Trends Neurosci. (2002) 25(5):253-259.
107. NASSAR MA, STIRLING LC, FORLANI G et al.: Nociceptor-specific gene deletion reveals a major role fo r Nav1.7 (PN1) in acute and inflammatory pain. Proc. Natl. Acad. Sci. USA (2004) 101(34):12706-12711.
108. NASSAR MA, LEVATO A, STIRLING LC, WOOD JN: Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Mol. Pain (2005) 1:24.
109. DIB-HAJJ SD, RUSH AM, CUMMINS TR et al.: Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain (2005) 128(Pt 8):1847-1854.
110. FERTLEMAN CR, BAKER MD, PARKER KA et al.: SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron (2006) 52(5):767-774.
111. COX JJ, REIMANN F, NICHOLAS AK et al.: An SCN9A channelopathy causes congenital inability to experience pain. Nature (2006) 444(7121):894-898.
112. CLARK RJ, FISCHER H, DEMPSTER L et al.: Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. Proc. Natl. Acad. Sci. USA (2005) 102(39):13767-13772.
113. HARVEY AJ, GABLE RW, BAELL JB: A three-residue, continuous binding epirope peptidomimetic of ShK toxin as a Kv1.3 inhibitor. Bioorg. Med. Chem. Lett. (2005) 15(13):3193-3196.
114. LI C, DOWD CS, ZHANG W, CHAIKEN IM: Phage randomization in a charybdotoxin scaffold leads to CD4-mimetic recognition motifs that bind HIV-1 envelope through non-aromatic sequences. J. Pept. Res. (2001) 57(6):507-518.
115. BAELL JB, DUGGAN PJ, FORSYTH SA, LEWIS RJ, LOK YP, SCHROEDER CI: Synthesis and biological evaluation of nonpeptide mimetics of omega-conotoxin GVIA. Bioorg. Med. Chem. (2004) 12(15):4025-4037.
116. BAELL JB, HARVEY AJ, NORTON RS: Design and synthesis of type-III mimetics of ShK toxin. J. Comput. Aided Mol. Des. (2002) 16(4):245-262.
117. BAELL JB, FORSYTH SA, GABLE RW, NORTON RS, MULDER RJ: Design and synthesis of type-III mimetics of omega-conotoxin GVIA. J. Comput. Aided Mol. Des. (2001) 15(12):1119-1136.